Sign in
Taking people in United StatesPhase 2

Imaging Agent 124I-Evuzumitide for Detecting Amyloid Deposits in Systemic Amyloidosis

Tests an imaging agent to detect amyloid deposits in the heart and other organs.

Key facts

Who runs it
Oregon Health and Science University
Where
Portland, United StatesSee the site
Trial code
Registry title
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Status
Recruiting
Phase
Phase 2
People taking part
150 people, planned
Started
10 Jan 2023
Expected to end
10 Mar 2028
Type of study
Interventional
Treatments tested
  • 124I-Evuzamitide
Record updated
13 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with systemic amyloidosis, a known transthyretin gene mutation, multiple myeloma or monoclonal gammopathy of undetermined significance. They will have PET imaging with 124I-evuzumitide.

Age
40 to 90 years
Sex
All sexes can join.
Disease stage
Systemic amyloidosis with known organ involvement, or carrier of a known pathogenic transthyretin gene mutation, or multiple myeloma, or monoclonal gammopathy of undetermined significance.
Earlier treatment
Cannot have received heparin or heparin analogs (such as enoxaparin, dalteparin, fondaparinux) within 7 days before the study drug.
Biomarker or test result
A known pathogenic mutation in the transthyretin gene counts for carriers; otherwise none is asked for.

Main reasons for not taking part

  • Severe claustrophobia or a medical condition that prevents finishing the imaging
  • Known allergy to potassium iodide treatment or to gadolinium
  • Heparin or heparin analogs within 7 days before 124I-Evuzumitide
  • Dialysis or eGFR <30 cc/min/1.73 m2 (cannot have gadolinium-enhanced cardiac MRI)

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Subjects will at least have one of the following conditions: systemic amyloidosis with known organ involvement, carrier of a known pathogenic mutation in the transthyretin gene, multiple myeloma, and monoclonal gammopathy of undetermined significance
  • Patient willing to consent for the study and undergo the study procedures

Who cannot take part

  • Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within 7 days prior to 124I-Evuzumitide administration
  • Has severe claustrophobia or any medical condition that would prevent completion of the imaging protocol
  • Has a known allergy to potassium iodide treatment or to gadolinium
  • Patients on dialysis or those with eGFR <30 cc/min/1.73 m2 will be excluded from undergoing gadolinium-enhanced cardiac MRI

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 90 years old?

Where in United States

  • Oregon Health Science UniversityPortland, United StatesContact: Ahmad Masri, MDTaking people

About the trial

What the trial wants to find out

This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in cardiac amyloidosis 2) Evaluate extracardiac uptake 3) identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 4) Correlate the uptake with the structure and function of different organs, including the heart. To achieve these goals, eligible patients will undergo primarily hybrid positron emission tomography and magnetic resonance imaging (PET/MRI). In a subgroup of patients who are unable to undergo PET/MR, computed tomography will be used instead of MRI (i.e. PET/CT). In a subgroup of patients, repeat imaging with the same modality will be done at a interval of 6-12 months. Clinically available data (demographics, phenotype, imaging, laboratory) will also be collected to characterize the disease in each patient.

The group in the trial

  • Patients with ATTR-CMTreatment being tested

    Patients with ATTR-CM will undergo hybrid 124I-Evuzamitide PET/MRI imaging (or PET/CT) at baseline and in a subgroup, repeat imaging will be performed at an interval of 6-12 months.

    Treatment: 124I-Evuzamitide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Plain-language title
Imaging Agent 124I-Evuzumitide for Detecting Amyloid Deposits in Systemic AmyloidosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05758493, who can take part
Publications
Record updated
13 April 2026